ZURICH, Switzerland, June 8, 2020 /PRNewswire/ -- HeiQ Viroblock NPJ03 is among the first textile technologies in the world to be proven effective against SARS-CoV-2 in the laboratory. Tests conducted by Swiss textile innovator HeiQ [http://www.heiq.com/] with the Peter Doherty Institute [https://www.doherty.edu.au/] for Infection and Immunity in Melbourne, Australia (Doherty Institute) showed that treated fabric achieved 99.99% reduction of the virus.
HeiQ Viroblock NPJ03 [http://www.heiq.com/heiq-viroblock] is a textile treatment for industrial use, designed to provide textiles with antiviral and antibacterial properties. The combination of silver antimicrobial technology and vesicle technology rapidly destroy enveloped viruses including coronaviruses. It has previously been tested against coronavirus 229E, another strain of virus in the Coronavirus family.
The latest testing with SARS-CoV-2 virus was conducted by researchers at the Doherty Institute, a joint venture between the University of Melbourne and The Royal Melbourne Hospital, an internationally renowned institution combining research, teaching, public health and reference laboratory services, diagnostic services and clinical care into infectious diseases and immunity.
The research project involved a disinfection test protocol that simulated the real-life interaction of small aerosol droplets contaminating clothing. A known concentration of SARS-CoV-2 virus was contacted with the sample fabric for 30 minutes followed by measurement of remaining infectious SARS-CoV-2 viruses.
The fabric sample treated with HeiQ Viroblock NPJ03 had no infective viruses left after 30 minutes. The result indicated a SARS-CoV-2 virus reduction of 99.99% relative to the inoculum control.
Carlo Centonze, Swiss co-founder and Chief Executive Officer of HeiQ Group, stated, "The confirmation of antiviral activity of HeiQ Viroblock against SARS-CoV-2 is an important milestone. This data forms part of our ongoing efforts to help provide textiles with greater levels of protection against viruses and contribute to efforts towards mitigation of the global pandemic."
"HeiQ appreciates the work of the Doherty Institute in conducting these tests and the tremendous efforts of their researchers in contributing to the global understanding of the COVID-19 pandemic," says Australian Dr. Murray Height, co-founder and Chief Science Officer of HeiQ Group.
Dr. Julie McAuley, Senior Research Officer at the Doherty Institute, stated, "A key part of the Institute's current COVID-19 research focus is on testing different ways to achieve an antiviral effect against the SARS-CoV-2 virus."
"Testing the action of different disinfectants and surface treatments is one way that our research can help provide insights towards helping to stop the pandemic," Dr. McAuley added.
Sign up for the press conference: CLICK HERE [https://heiq.com/2020/06/05/heiq-viroblock-tested-successfully-against-virus-that-causes-covid-19]
Founded in 2005 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH), HeiQ is a leader in textile innovation creating some of the most effective, durable and high-performance textile technologies on the market today. HeiQ's purpose is to improve the lives of billions of people by perfecting an everyday product: Textiles. Combining three areas of expertise - scientific research, specialty materials manufacturing and consumer ingredient branding - HeiQ is the ideal innovation partner to create differentiating and sustainable textile products and capture the added value at the point of sale. With a total capacity of 35'000 tons per year HeiQ manufactures in the USA, Switzerland and Australia serving its chemical specialties in over 60 countries worldwide.
HeiQ, Viroblock and HeiQ Viroblock are trademark(s) or registered trademark(s) of HeiQ Materials AG. The use of such trademark(s) is subject to approval from HeiQ.
HeiQ Materials AG To sign up for the press conference,
8952 Schlieren (Zurich)
www.heiq.com For inquiries about HeiQ Viroblock
face masks, send an email to
USA: +1-704-795-9322 For other questions, send an email to
About the Doherty Institute
Finding solutions to prevent, treat and cure infectious diseases and understanding the complexities of microbes and the immune system requires innovative approaches and concentrated effort. This is why the University of Melbourne [http://www.unimelb.edu.au/] - a world leader in education, teaching and research excellence - and The Royal Melbourne Hospital [http://www.thermh.org.au/] - an internationally renowned institution providing outstanding care, research and learning - partnered to create the Peter Doherty Institute for Infection and Immunity (Doherty Institute); a centre of excellence where leading scientists and clinicians collaborate to improve human health globally.
792 Elizabeth Street
Melbourne VIC 3000
Logo: https://mma.prnewswire.com/media/1134330/HeiQ_Materials_Logo.jpg [https://mma.prnewswire.com/media/1134330/HeiQ_Materials_Logo.jpg] Photo: https://mma.prnewswire.com/media/1177576/HeiQ_Viroblock.jpg [https://mma.prnewswire.com/media/1177576/HeiQ_Viroblock.jpg]